Study of I Line FOLFOX + Panitumumab vs 5FU + Panitumumab in RAS and BRAF WT Metastatic Colorectal Cancer Elderly Patients

Inclusion criteria

* Written informed consent to study procedures and to molecular analyses.
* Histologically proven diagnosis of colorectal cancer.
* Initially unresectable metastatic colorectal cancer not previously treated with chemotherapy for metastatic disease.
* At least one measurable lesion according to RECIST1.1 criteria.
* Availability of a tumoral sample (primary and/or metastatic sites).
* Age ≥ 70 years.
* ECOG PS 1 or 2 for patients aged 70 to 75 years; ECOG PS 0 or 1 for patients aged \> 75 years.
* Life expectancy of at least 12 weeks.
* Previous adjuvant chemotherapy allowed only if with fluoropyrimidine monotherapy and more than 6 months elapsed between the end of adjuvant and first relapse.
* RAS and BRAF status wild-type of primary colorectal cancer or related metastasis, centrally assessed.
* Neutrophils ≥1.5 x 109/L, Platelets ≥100 x 109/L, Hgb ≥ 9 g/dl.
* Total bilirubin ≤ 1.5 time the upper-normal limits (UNL) of the normal values and ASAT (SGOT) and/or ALAT (SGPT) ≤ 2.5 x UNL (or \<5 x UNL in case of liver metastases) alkaline phosphatase ≤ 2.5 x UNL (or \<5 x UNL in case of liver metastases).
* Creatinine clearance ≥ 50 mL/min or serum creatinine ≤1.5 x UNL.
* Male subjects with female partners of childbearing potential must be willing to use adequate contraception as approved by the investigator (barrier contraceptive measure or oral contraception).
* Geriatric assessment by means of G8 screening tool and CRASH score.
* Will and ability to comply with the protocol.

Exclusion criteria

* Previous treatment for metastatic disease.
* Radiotherapy to any site within 4 weeks before the study.
* Previous adjuvant oxaliplatin-containing chemotherapy.
* Previous treatment with EGFR inhibitors.
* Untreated brain metastases or spinal cord compression or primary brain tumors.
* History or evidence upon physical examination of CNS disease unless adequately treated.
* Symptomatic peripheral neuropathy \> 1 grade NCIC-CTG criteria.
* Creatinine clearance \< 50 mL/min or serum creatinine \>1.5 x UNL.
* Clinical signs of malnutrition.
* Neutrophils \<1.5 x 109/L, Platelets \<100 x 109/L, Hgb \<9 g/dl.
* Diagnosis of interstitial pneumonitis or pulmonary fibrosis.
* Active uncontrolled infections or other clinically relevant concomitant illness contraindicating chemotherapy administration.
* Clinically significant (i.e. active) cardiovascular disease for example cerebrovascular accidents (≤6 months), myocardial infarction (≤6 months), unstable angina, New York Heart Association (NYHA) grade II or greater congestive heart failure (CHF), serious cardiac arrhythmia requiring medication.
* Treatment with any investigational drug within 30 days prior to enrollment or 2 investigational agent half-lives (whichever is longer)
* Other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of localized basal and squamous cell carcinoma or cervical cancer in situ.
* Lack of physical integrity of the upper gastrointestinal tract, malabsorption syndrome, or inability to take oral medication.
* Definite contraindications for the use of corticosteroids and antihistamines as premedication.
* Known hypersensitivity to trial drugs or hypersensitivity to any other component of the trial drugs.
* Any concomitant drugs contraindicated for use with the trial drugs according to the product information of the pharmaceutical companies.
* Sexually active males unwilling to practice contraception (barrier contraceptive measure or oral contraception) during the study and until 6 months after the last trial treatment.